Document Detail

Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children.
MedLine Citation:
PMID:  7630925     Owner:  NLM     Status:  MEDLINE    
Cholestasis can be defined as the manifestation of defective bile acid transport from the liver to the intestine. Most chronic cholestatic conditions can progress towards cirrhosis. At this stage, liver transplantation is the treatment of choice. Most of the drugs so far evaluated show some degree of efficacy but have major side effects. Given that ursodeoxycholic acid (UDCA) has no apparent toxicity in humans, it was postulated that long-term treatment with this drug might displace endogenous bile acids and thus reverse their suspected toxicity. We demonstrated that long-term UDCA therapy slows the progression of primary biliary cirrhosis and reduces the need for liver transplantation. In this review, we give the rationale for the use of UDCA in cholestasis and discuss its possible mechanisms of action. We also give an overview of current data on UDCA therapy of chronic cholestatic disorders in adults and children.
R Poupon; R E Poupon
Related Documents :
12885265 - Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical ...
8276175 - Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeox...
3819605 - An argument that all prerandomized clinical trials are unethical.
8276045 - Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. changes in b...
2820085 - The effects of perfluoro-n-decanoic acid (pfda) on rat heart beta-receptors, adenylate ...
9621235 - The effect of preservatives based on propionic acid on the fermentation and aerobic sta...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pharmacology & therapeutics     Volume:  66     ISSN:  0163-7258     ISO Abbreviation:  Pharmacol. Ther.     Publication Date:  1995 Apr 
Date Detail:
Created Date:  1995-09-07     Completed Date:  1995-09-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7905840     Medline TA:  Pharmacol Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1-15     Citation Subset:  IM    
Unité d'Hépato-Gastroentérologie, Hôpital Saint-Antoine, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bile Acids and Salts / metabolism
Cholestasis / drug therapy*,  etiology
Clinical Trials as Topic
Cystic Fibrosis / complications
Intestinal Absorption / drug effects
Liver / drug effects,  metabolism
Pregnancy Complications / drug therapy
Ursodeoxycholic Acid / administration & dosage,  pharmacology,  therapeutic use*
Reg. No./Substance:
0/Bile Acids and Salts; 128-13-2/Ursodeoxycholic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effect of essential fatty acid supplementation on keratinocyte replication.
Next Document:  5-Hydroxytryptamine pathways in anxiety and its treatment.